Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2018 | Pages:
153 | Publisher: Grand View Research
Industry: Healthcare | Report Format: Electronic (PDF)
The global epigenetics market size is expected to reach USD 22.05 billion by 2025, according to a new study by Grand View Research, Inc., progressing at a CAGR of 19.7% during the forecast period. Growing prevalence of cancer and other diseases worldwide with epigenetic modification base is expected to drive the market during the forecast period. Diagnostic companies are coming up with new products such as antibodies specific for detection of modifications and new upgraded kits for easy and efficient detection of biomarkers. This is estimated to attract pharmaceutical companies to collaborate for development of therapeutic drugs, which will work in favor of the market. Presence of pipeline drugs and their expected commercialization is anticipated to boost the growth of the market. For instance, Ramucirumab (Cyramza) by Eli Lilly and Company was approved by FDA for use in combination with Folfiri for treatment of patients with metastatic colorectal cancer. Technology advancements in the epigenetics industry are majorly focusing on detection of methylation markers related to cancer development. For instance, Epi proLung BL Reflex Assay by Epigenomics helps in diagnosis of lung cancer by determining methylation of SHOX2 biomarker gene. Further key findings from the study suggest: • On the basis of product, reagents held the largest share in the market in 2017. They are projected to amount to approximately USD 7.06 billion by 2025 owing to increasing R&D activities in the field of epigenetics • The kits segment is expected to post a CAGR of over 20.0% due to need for rapid and accurate detection techniques • DNA methylation, on the basis of technology, held the leading revenue share in the market in 2017, accounting for just over 47.0%. Rapid adoption of advanced techniques such as methylation sensitive PCR (MSP) to improve diagnostics efficiency is poised to bolster the growth of the segment • North America commanded the leading position in the global arena with a share of 40.0% in 2017. The growth of the regional market can be attributed to increasing prevalence of cancer and growing collaborations between large pharmaceutical firms for development of improved therapeutics • Asia Pacific is estimated to register a noteworthy CAGR of 22.1% during the forecast period owing to presence of large target population coupled with high unmet clinical needs • Some of the major players of epigenetics market are Illumina; Abcam; Diagenode; Thermo Fisher Scientific; Merck; Zymo research; Qiagen; CellCentric Ltd; Chroma Therapeutics Ltd; Eisai Co. Ltd; Novartis International AG; Oncolys Biopharma Inc.; Syndax Pharmaceuticals, Inc.; Valirx Plc; and Sigma-Aldrich Corporation • Extensive R&D initiatives for development of novel drugs and presence of strong product pipeline are expected to further boost market growth over the forecast period.
Table of Contents
Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Information or Data Analysis
1.3 Market Formulation & Validation
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Market Variables, Trends & Scope
Chapter 4 Epigenetics Market Variables, Trends & Scope
4.1 Market Segmentation
4.2 Market Size and Growth Prospects
4.2.1 Market driver analysis
4.2.1.1 Increasing prevalence of target diseases
4.2.1.2 Growing global geriatric population
4.2.1.3 Increasing collaborations between biotechnology companies, pharmaceutical companies, and academic research institutes
4.2.1.4 Presence of funding programs to promote and support research & development
4.2.1.5 Technological advancements
4.2.2 Market restraint analysis
4.2.2.1 Inefficiency in identification and validation of biomarkers
4.2.2.2 Presence of complex regulatory framework
4.3 Key Opportunities Prioritized
4.4 Epigenetics - SWOT Analysis, by Factor (Political & legal, economic and technological)
4.5 Industry Analysis - Porter's
4.6 Epigenetics-Pipeline overview
Chapter 5 Epigenetics Market Product Estimates & Trend Analysis
5.1 Epigenetics Market: Product Movement Analysis
5.2 Epigenetics-based reagents
5.2.1 Epigenetics-based reagents, 2014 - 2025 (USD Million)
5.3 Epigenetics-based kits
5.3.1 Epigenetics-based kits, 2014 - 2025 (USD Million)
5.3.2 ChIP sequencing kit
5.3.2.1 ChIP sequencing kit Market, 2014 - 2025 (USD Million)
5.3.3 Whole-genomic amplification kit
5.3.3.1 Whole-genomic amplification kit Market, 2014 - 2025 (USD Million)
5.3.4 Bisulfite conversion kit
5.3.4.1 Bisulfite conversion kit Market, 2014 - 2025 (USD Million)
5.3.5 RNA sequencing Kit
5.3.5.1 RNA sequencing Kit Market, 2014 - 2025 (USD Million)
5.3.5.2 Others
5.3.6 Others kit Market, 2014 - 2025 (USD Million)
5.4 Epigenetics-based instruments Market
5.4.1 Epigenetics-based instruments Market, 2014 - 2025 (USD Million)
5.5 Epigenetics-based enzymes Market
5.5.1 Epigenetics-based enzymes Market, 2014 - 2025 (USD Million)
5.6 Epigenetics-based services market
5.6.1 Epigenetics-based services Market, 2014 - 2025 (USD Million)
Chapter 6 Epigenetics Market Technology Estimates & Trend Analysis
6.1 Epigenetics Market: Technology Movement Analysis
6.2 Epigenetics-based DNA methylation market
6.2.1 Epigenetics-based DNA methylation market, 2014 - 2025 (USD Million)
6.3 Epigenetics-based histone methylation market
6.3.1 Epigenetics-based histone methylation market, 2014 - 2025 (USD Million)
6.4 Epigenetics-based histone acetylation market
6.4.1 Epigenetics-based histone acetylation market, 2014 - 2025 (USD Million)
6.5 Epigenetics-based long non-coding RNA market
6.5.1 Epigenetics-based long non-coding RNA market, 2014 - 2025 (USD Million)
6.6 Epigenetics-based microRNA modification market
6.6.1 Epigenetics-based microRNA modification market, 2014 - 2025 (USD Million)
6.7 Epigenetics-based Chromatin structures market
6.7.1 Epigenetics-based Chromatin structures market, 2014 - 2025 (USD Million)
Chapter 7 Epigenetics Market Application Estimates & Trend Analysis
7.1 Epigenetics Market: Application Movement Analysis
7.2 Oncology
7.2.1 Oncology market, 2014 - 2025 (USD Million)
7.2.2 Solid tumors
7.2.3 Solid tumors market, 2014 - 2025 (USD Million)
7.2.4 Liquid tumors
7.2.5 Liquid tumors market, 2014 - 2025 (USD Million)
7.3 Non-oncology disorders
7.3.1 Non-oncology disorders market, 2014 - 2025 (USD Million)
7.3.2 Inflammatory diseases
7.3.3 Inflammatory diseases market, 2014 - 2025 (USD Million)
7.3.4 Metabolic diseases
7.3.5 Metabolic diseases market, 2014 - 2025 (USD Million)
7.3.6 Infectious diseases
7.3.7 Infectious diseases market, 2014 - 2025 (USD Million)
7.3.8 Cardiovascular diseases
7.3.9 Cardiovascular diseases market, 2014 - 2025 (USD Million)
7.3.10 Others
7.3.11 Others market, 2014 - 2025 (USD Million)
Chapter 8 Regional Estimates & Trend Analysis, by Product
8.1 Epigenetics market share by region, 2017 & 2025
8.2 North America
8.2.1 North America epigenetics market, 2014 - 2025 (USD Million)
8.2.2 U.S.
8.2.2.1 U.S. epigenetics market, 2014 - 2025 (USD Million)
8.2.3 Canada
8.2.3.1 Canada epigenetics market, 2014 - 2025 (USD Million)
8.3 Europe
8.3.1 Europe epigenetics market, 2014 - 2025 (USD Million)
8.3.2 Germany
8.3.2.1 Germany epigenetics market, 2014 - 2025 (USD Million)
8.3.3 U.K.
8.3.3.1 U.K. epigenetics market, 2014 - 2025 (USD Million)
8.4 Asia Pacific
8.4.1 Asia Pacific epigenetics market, 2014 - 2025 (USD Million)
8.4.2 Japan
8.4.2.1 Japan epigenetics market, 2014 - 2025 (USD Million)
8.4.3 China
8.4.3.1 China epigenetics market, 2014 - 2025 (USD Million)
8.4.4 India
8.4.4.1 India epigenetics market, 2014 - 2025 (USD Million)
8.5 Latin America
8.5.1 Latin America epigenetics market, 2014 - 2025 (USD Million)
8.5.2 Brazil
8.5.2.1 Brazil epigenetics market, 2014 - 2025 (USD Million)
8.5.3 Mexico
8.5.3.1 Mexico epigenetics market, 2014 - 2025 (USD Million)
8.6 MEA
8.6.1 MEA epigenetics market, 2014 - 2025 (USD Million)
8.6.2 South Africa
8.6.2.1 South Africa epigenetics market, 2014 - 2025 (USD Million)
Chapter 9 Competitive Landscape
9.1 Strategy Framework
9.2 Illumina, Inc.
9.2.1 Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.3 Merck Sharp & Dohme Corp
9.3.1 Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.4 Qiagen
9.4.1 Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.5 F. Hoffmann-La Roche Ltd.
9.5.1 Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.6 Eisai Co., Ltd.
9.6.1 Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.7 Novartis AG
9.7.1 Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.8 Abcam plc
9.8.1 Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.9 Diagenode Diagnostics
9.9.1 Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.10 Thermo Fisher Scientific, Inc.
9.10.1 Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.11 Active Motif
9.11.1 Company overview
9.11.2 Financial performance
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
9.12 Zymo Research Corporation
9.12.1 Company overview
9.12.2 Financial performance
9.12.3 Product benchmarking
9.12.4 Strategic initiatives
9.13 CellCentric
9.13.1 Company overview
9.13.2 Product benchmarking
9.13.3 Strategic initiatives
9.14 Chroma Therapeutics Ltd.
9.14.1 Company overview
9.14.2 Financial performance
9.14.3 Product benchmarking
9.14.4 Strategic initiatives
9.15 Oncolys BioPharma Inc.
9.15.1 Company overview
9.15.2 Financial performance
9.15.3 Product benchmarking
9.15.4 Strategic initiatives
9.16 Syndax
9.16.1 Company overview
9.16.2 Financial performance
9.16.3 Product benchmarking
9.16.4 Strategic initiatives
9.17 Valirx
9.17.1 Company overview
9.17.2 Financial performance
9.17.3 Product benchmarking
9.17.4 Strategic initiatives
9.18 Sigma-Aldrich Corporation (Merck KGaA)
9.18.1 Company overview
9.18.2 Financial performance
9.18.3 Product benchmarking
9.18.4 Strategic initiatives
List of Tables TABLE 1 Global cancer cases, 2016 TABLE 2 Some major collaboration in epigenetic market TABLE 3 List of key organizations funding epigenetics related R&D worldwide TABLE 4 Pipeline and new product development analysis
List of Figures FIG. 1 Market research process FIG. 2 Information procurement FIG. 3 Primary research pattern FIG. 4 Market research approaches FIG. 5 Value chain based sizing & forecasting FIG. 6 QFD modelling for market share assessment FIG. 7 Market summary FIG. 8 Market trends & outlook FIG. 9 Market segmentation & scope FIG. 10 Global epigenetics market, 2014 - 2025 (USD Million) FIG. 11 Market driver relevance analysis (Current & future impact) FIG. 12 Global population by age group, 2000 - 2050 (in billion) FIG. 13 Population of age 60 years and above, by region (2015 & 2020) FIG. 14 Market restraint relevance analysis (Current & future impact) FIG. 15 Epigenetics key opportunities prioritized FIG. 16 SWOT Analysis, By Factor (political & legal, economic and technological) FIG. 17 Porter's Five Forces Analysis FIG. 18 Epigenetics market product outlook key takeaways FIG. 19 Epigenetics market: Product movement analysis FIG. 20 Epigenetics-based reagents, 2014 - 2025 (USD Million) FIG. 21 Epigenetics-based kits, 2014 - 2025 (USD Million) FIG. 22 ChIP sequencing kit Market, 2014 - 2025 (USD Million) FIG. 23 Whole-genomic amplification kit Market, 2014 - 2025 (USD Million) FIG. 24 Bisulfite conversion kit Market, 2014 - 2025 (USD Million) FIG. 25 RNA sequencing Kit Market, 2014 - 2025 (USD Million) FIG. 26 Others kit Market, 2014 - 2025 (USD Million) FIG. 27 Epigenetics-based instruments Market, 2014 - 2025 (USD Million) FIG. 28 Epigenetics-based enzymes Market, 2014 - 2025 (USD Million) FIG. 29 Epigenetics-based services market, 2014 - 2025 (USD Million) FIG. 30 Epigenetics market technology outlook key takeaways FIG. 31 Epigenetics market: Technology movement analysis FIG. 32 Epigenetics-based DNA methylation market, 2014 - 2025 (USD Million) FIG. 33 Epigenetics-based histone methylation market, 2014 - 2025 (USD Million) FIG. 34 Epigenetics-based histone acetylation market, 2014 - 2025 (USD Million) FIG. 35 Epigenetics-based long non-coding RNA market, 2014 - 2025 (USD Million) FIG. 36 Epigenetics-based microRNA modification market, 2014 - 2025 (USD Million) FIG. 37 Epigenetics-based Chromatin structures market, 2014 - 2025 (USD Million) FIG. 38 Epigenetics market application outlook key takeaways FIG. 39 Epigenetics market: Application movement analysis FIG. 40 Oncology market, 2014 - 2025 (USD Million) FIG. 41 Solid tumors market, 2014 - 2025 (USD Million) FIG. 42 Liquid tumors market, 2014 - 2025 (USD Million) FIG. 43 Non-oncology disorders market, 2014 - 2025 (USD Million) FIG. 44 Inflammatory diseases market, 2014 - 2025 (USD Million) FIG. 45 Metabolic diseases market, 2014 - 2025 (USD Million) FIG. 46 Infectious diseases market, 2014 - 2025 (USD Million) FIG. 47 Cardiovascular diseases market, 2014 - 2025 (USD Million) FIG. 48 Others market, 2014 - 2025 (USD Million) FIG. 49 Regional market place: Key takeaways FIG. 50 Epigenetics market: Regional movement analysis FIG. 51 North America epigenetics market, 2014 - 2025 (USD Million) FIG. 52 U.S. epigenetics market, 2014 - 2025 (USD Million) FIG. 53 Canada epigenetics market, 2014 - 2025 (USD Million) FIG. 54 Europe epigenetics market, 2014 - 2025 (USD Million) FIG. 55 Germany epigenetics market, 2014 - 2025 (USD Million) FIG. 56 U.K. epigenetics market, 2014 - 2025 (USD Million) FIG. 57 Asia Pacific epigenetics market, 2014 - 2025 (USD Million) FIG. 58 Japan epigenetics market, 2014 - 2025 (USD Million) FIG. 59 China epigenetics market, 2014 - 2025 (USD Million) FIG. 60 India epigenetics market, 2014 - 2025 (USD Million) FIG. 61 Latin America epigenetics market, 2014 - 2025 (USD Million) FIG. 62 Brazil epigenetics market, 2014 - 2025 (USD Million) FIG. 63 Mexico epigenetics market, 2014 - 2025 (USD Million) FIG. 64 MEA epigenetics market, 2014 - 2025 (USD Million) FIG. 65 South Africa epigenetics market, 2014 - 2025 (USD Million) FIG. 66 Strategy framework
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
